https://allsci.com/news/clinical-trials/nonsegmental-vitiligo-litfulo-phase-iii-data-back/ AllScien 2026-10-02T17:05:04.622425Z Litfulo Phase III data support Pfizer’s push into systemic vitiligo treatment https://allsci.com/news/clinical-trials/atopic-dermatitis-pfizers-trispecific-tilrekimig/ AllScien 2026-10-02T17:01:49.012568Z Pfizer’s tilrekimig delivers Phase II skin clearance ahead of dupilumab head-to-head https://allsci.com/news/biotech/ubamatamab-lgsoc-shows-early-promise-in-small/ AllScien 2026-10-02T16:57:16.825538Z Regeneron’s ubamatamab posts 73% response rate in small LGSOC cohort https://allsci.com/news/clinical-trials/trevogrumab-trial-courage-data-back-as-muscle/ AllScien 2026-10-02T16:27:17.650948Z Regeneron’s trevogrumab cuts lean-mass loss in Phase II obesity trial https://allsci.com/news/biotech/migraine-treatment-trigemx-bio-secures-usd-94m-to/ AllScien 2026-10-02T13:56:21.439204Z TriGemX Bio secures USD 94m to advance elismetrep Phase III migraine program https://allsci.com/news/licensing-and-partnerships/biosimilar-partnership-samsung-bioepis-and-teva/ AllScien 2026-10-02T11:45:31.683911Z Samsung Bioepis, Teva expand biosimilar alliance with up to six new programs https://allsci.com/news/licensing-and-partnerships/abogen-novartis-deal-secures-usd-575m-upfront/ AllScien 2026-10-02T10:56:13.235637Z Novartis pays USD 575m upfront for Abogen’s mRNA-encoded in vivo autoimmune TCE https://allsci.com/news/clinical-trials/prurigo-nodularis-qyuns-therapeutics-oturkibart/ AllScien 2026-10-02T10:42:27.183011Z Qyuns Therapeutics' oturkibart hits Phase III primary endpoint in prurigo nodularis https://allsci.com/news/biotech/datroway-ivonescimab-astrazeneca-and-daiichi/ AllScien 2026-10-02T10:26:58.697673Z AstraZeneca, Daiichi team with Summit to pair Datroway with ivonescimab in Phase III TNBC push https://allsci.com/news/biotech/alzheimers-vaccine-trial-nuravax-launches/ AllScien 2026-10-02T09:12:06.322320Z Nuravax launches first-in-human trial of dual-target Alzheimer's vaccine DUVAX https://allsci.com/news/clinical-trials/tj102-ovarian-cancer-trial-phrontline-opens-phase/ AllScien 2026-10-02T08:49:47.239168Z Phrontline brings FRα×CDH6 dual-payload ADC into the clinic in China, US https://allsci.com/news/clinical-trials/tulisokibart-hidradenitis-suppurativa-mercks/ AllScien 2026-10-02T08:34:52.185330Z Merck’s tulisokibart delivers first positive Phase II anti-TL1A data in dermatology https://allsci.com/news/clinical-trials/survodutide-weight-loss-trial-boehringers/ AllScien 2026-10-02T08:23:31.337491Z Boehringer’s survodutide hits Phase III endpoints with 13.1% weight loss in T2D https://allsci.com/news/biotech/zumilokibart-atopic-dermatitis-abbvies-cuts/ AllScien 2026-10-02T08:07:13.093101Z AbbVie’s zumilokibart clears Phase II with potential for quarterly or twice-yearly dosing https://allsci.com/news/biotech/series-b-funding-tbi-treatment-astrocyte-raises/ AllScien 2026-10-02T07:58:33.729280Z Astrocyte lands USD 9.5m Series B as AST-004 nears concussion data https://allsci.com/news/biotech/muc1-c-antibody-drug-conjugate-xyone-advances/ AllScien 2026-10-01T16:25:48.412068Z XYone advances first MUC1-C ADC into Phase 1b/2 solid tumor trial https://allsci.com/news/regulatory/medicare-drug-pricing-cms-finalizes-mandatory/ AllScien 2026-10-01T16:21:51.292393Z CMS finalizes scaled-back international drug pricing model for Medicare Part B https://allsci.com/news/biotech/clinical-trials-hhs-launches-surpass-program/ AllScien 2026-10-01T16:11:46.861386Z ARPA-H takes aim at decade-long drug development with SURPASS trial overhaul https://allsci.com/news/biotech/foghorn-layoffs-cuts-40-staff-as-fhd-909-program/ AllScien 2026-10-01T16:01:23.005039Z Foghorn cuts 40% of staff as Lilly pulls out of FHD-909 program https://allsci.com/news/regulatory-policy/fda-advisory-committees-launches-nationwide/ AllScien 2026-10-01T14:50:19.084611Z FDA seeks fresh scientific and consumer expertise for advisory committees https://allsci.com/news/biotech/tabelecleucel-fda-approval-atara-resubmits/ AllScien 2026-10-01T14:19:10.055044Z Pierre Fabre, Atara resubmit Ebvallo BLA after two FDA CRLs https://allsci.com/news/clinical-trials/pro-1562-multiple-sclerosis-trial-progentos/ AllScien 2026-10-01T13:56:46.002274Z Progentos takes oral remyelination drug PRO-1562 into first human MS trial https://allsci.com/news/approvals/camzyos-pediatric-cardiomyopathy-fda-expands/ AllScien 2026-10-01T13:35:14.558382Z FDA expands Bristol Myers Squibb's Camzyos into pediatric obstructive hypertrophic cardiomyopathy https://allsci.com/news/biotech/ai-protein-models-enzyme-therapy-profluent-taps/ AllScien 2026-10-01T12:54:02.752048Z BioMarin taps Profluent AI models for novel enzyme therapies https://allsci.com/news/biotech/regeneron-sanofi-il-4-il-13-alliance-and-expand/ AllScien 2026-10-01T12:42:56.158554Z Sanofi commits up to USD 8b for Regeneron’s long-acting immunology antibodies https://allsci.com/news/biotech/therapeutics-expands-series-r1-to-805-million-to/ AllScien 2026-10-01T09:51:12.964505Z R1 Therapeutics expands Series A to USD 80.5m as AP306 nears Phase IIb readout https://allsci.com/news/biotech/gsk-wave-spina-sirna-hepatology-selects-waves/ AllScien 2026-10-01T09:16:45.499113Z Wave lands USD 12m as GSK advances SpiNA siRNA program https://allsci.com/news/clinical-trials/eloratzp-obesity-diabetes-trial-lillys/ AllScien 2026-10-01T08:36:39.236239Z Lilly's EloraTZP combination tops tirzepatide alone in Phase IIb obesity and diabetes trial https://allsci.com/news/biotech/thermostable-mrna-vaccines-mit-researchers/ AllScien 2026-09-30T17:57:59.317114Z MIT uses AI to create mRNA vaccines stable for months without ultra-cold storage https://allsci.com/news/clinical-trials/abbv-295-obesity-trial-abbvies-amylin-analog/ AllScien 2026-09-30T17:48:29.746749Z AbbVie’s ABBV-295 supports monthly dosing after Phase I obesity study